BRIEF-Prothena Announces That Novo Nordisk Will Advance Coramitug Into Phase 3 Development

Reuters
Aug 06
BRIEF-Prothena Announces That <a href="https://laohu8.com/S/NVO">Novo Nordisk</a> Will Advance Coramitug Into Phase 3 Development

Aug 6 (Reuters) - Prothena Corporation PLC PRTA.O:

  • PROTHENA ANNOUNCES THAT NOVO NORDISK WILL ADVANCE CORAMITUG (FORMERLY PRX004) INTO PHASE 3 DEVELOPMENT FOR ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY

  • PROTHENA CORPORATION: UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE UP TO $1.2 BILLION DOLLARS UPON ACHIEVEMENT OF CLINICAL DEVELOPMENT & SALES MILESTONES

Source text: ID:nBw6ylMXVa

Further company coverage: PRTA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10